SEC Company Response from Phio Pharmaceuticals Corp. (PHIO) (CIK 0001533040) (PHIO) — Sep 28, 2018
Phio Pharmaceuticals Corp. (PHIO) (CIK 0001533040)
Date: Sept. 28, 2018 · CIK: 0001533040 · Accession: 0001683168-18-002884
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-227173
Letter
Re: RXi Pharmaceuticals Corporation
September 28, 2018
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form S-1 (Registration No. 333-227173)
Concurrence in Acceleration Request
Ladies and Gentlemen:
H.C. Wainwright & Co., LLC (“Wainwright”), as underwriter for the referenced offering, hereby concurs in the request by RXi Pharmaceuticals Corporation that the effective date of the above-referenced registration statement be accelerated to 5:00 p.m. (Eastern Time), or as soon as practicable thereafter, on September 28, 2018, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act in connection with this offering.
Very truly yours,
H.C. WAINWRIGHT & CO., LLC
Show Raw Text
CORRESP
1
filename1.htm
September 28, 2018
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
RXi Pharmaceuticals Corporation
Registration Statement on Form S-1 (Registration No. 333-227173)
Concurrence in Acceleration Request
Ladies and Gentlemen:
H.C. Wainwright &
Co., LLC (“Wainwright”), as underwriter for the referenced offering, hereby concurs in the request by RXi Pharmaceuticals
Corporation that the effective date of the above-referenced registration statement be accelerated to 5:00 p.m. (Eastern Time),
or as soon as practicable thereafter, on September 28, 2018, pursuant to Rule 461 under the Securities Act. Wainwright affirms
that it is aware of its obligations under the Securities Act in connection with this offering.
Very truly yours,
H.C. WAINWRIGHT & CO., LLC
By:
/s/ Mark W. Viklund
Name: Mark W. Viklund
Title: Chief Executive Officer